Form 8-K - Current report:
SEC Accession No. 0001140361-20-012787
Filing Date
2020-06-01
Accepted
2020-06-01 08:30:45
Documents
4
Period of Report
2020-06-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8K nt10011234x7_8k.htm 8-K 20472
2 EXHIBIT 1.1 nt10011234x7_ex1-1.htm EX-1.1 260416
3 EXHIBIT 4.1 nt10011234x7_ex4-1.htm EX-4.1 64987
4 EXHIBIT 5.1 nt10011234x7_ex5-1.htm EX-5.1 10208
  Complete submission text file 0001140361-20-012787.txt   357272
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 20931061
SIC: 2836 Biological Products, (No Diagnostic Substances)